

Trifexis

Version 2.4

Revision Date 04/29/2010

Print Date 01/12/2011

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Trifexis
Substance Number : 000000000962
Common Name : Spinosad, Milbemycin Oxime Tablets for Dogs

Company : Elanco Animal Health
Division of Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285

Telephone : 1-888-767-5023
Emergency telephone : CHEMTREC: 1-800-424-9300 (Outside U.S. 1-703-527-3887)

Item Code : CA4337, CA4339, CA4341, CA4342, CA4344, CA4332, CA4333, CA4334, CA4335, CA4336

SECTION 2. HAZARDS IDENTIFICATION**Emergency Overview****Lilly Lab Labeling Code****Health:** 1**Fire:** 1**Reactivity:** 0**Primary Hazards:** Not hazardous if intact, Liver, Kidney, Bone Marrow**Hazard Summary (Caution):** Effects of exposure to contents: May cause liver effects. May cause kidney effects. May cause bone marrow effects.**Emergency Overview**

Form : tablet
Colour : tan
Odour : musty

Potential Health Effects

Eyes : Effects of exposure to contents: May cause mild or transient irritation.
Skin : Effects of exposure to contents: May cause mild or transient irritation.

Trifexis

Version 2.4

Revision Date 04/29/2010

Print Date 01/12/2011

Aggravated Medical Condition : None known.

Primary Routes of Entry : Skin contact

Additional Information : This product is intended for animal consumption under guidance of a veterinarian. Animal studies have reported the following effects: Liver effects. Kidney effects. Bone marrow changes. (spinosad)

Carcinogenicity

NTP No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

IARC No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS-No.	Concentration [%]
Spinosyn A	131929-60-7	50
Spinosyn D	131929-63-0	9
Milbemycin A4 5-oxime	93074-04-5	0.7
Milbemycin A3 5-oxime	114177-14-9	0.2
Excipients	NA	40

NA = Not applicable, Not assigned, or Not available.

SECTION 4. FIRST AID MEASURES

General advice : Intact capsules or tablets are not considered hazardous under normal handling procedures.

Inhalation : If crushed and exposure to content occurs: Remove to fresh air. Consult a physician.

Skin contact : Wash off with soap and water. Get medical attention if irritation develops and persists.

Eye contact : If crushed and exposure to content occurs: Immediately flush eye(s) with plenty of water. Obtain medical attention.

Ingestion : If conscious, give the victim plenty of water to drink. Never give anything by mouth to an unconscious person. Call a physician immediately.

SECTION 5. FIRE-FIGHTING MEASURES

Trifexis

Version 2.4

Revision Date 04/29/2010

Print Date 01/12/2011

Skin and body protection : Chemical-resistant gloves and impermeable body covering to minimize skin contact. If handled in a ventilated enclosure, as in a laboratory setting, respirator and goggles or face shield may not be required. Safety glasses are always required.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Form	: tablet	Colour	: tan
Physical state	: solid	Odour	: musty

Safety data

Flash point	: not applicable	Upper explosion limit	: no data available
Lower explosion limit	: no data available	Water solubility	: no data available

SECTION 10. STABILITY AND REACTIVITY

Materials to avoid : Strong oxidizing agents

Hazardous decomposition products : Hazardous decomposition products formed under fire conditions.

Thermal decomposition : Stable under normal conditions.

Hazardous reactions : Hazardous polymerisation does not occur.

SECTION 11. TOXICOLOGICAL INFORMATION

Acute oral toxicity

- Spinosad: LD50 (male rat) 4,444 mg/kg
LD50 (female rat) > 5,000 mg/kg
LDLo (dog) > 400 mg/kg

Acute inhalation toxicity

- Spinosad: LC50 (rat) > 5,180 mg/m³ (4 h)

Acute dermal toxicity

- Spinosad: LD50 (rabbit) > 5,000 mg/kg

Skin irritation

- Spinosad: rabbit, No irritation

Eye irritation

Trifexis

Version 2.4

Revision Date 04/29/2010

Print Date 01/12/2011

- Spinosad: rabbit, slight irritation

Sensitisation

- Spinosad: guinea pig, Did not cause sensitization on laboratory animals.

Repeated dose toxicity

- Spinosad: In animals, has been shown to cause vacuolation of cells in liver, kidney, and bone tissues and changes in blood and serum biochemistry. Dose levels producing these effects were many times higher than any dose levels expected from exposure due to use.

Carcinogenicity

- Spinosad: Animal testing did not show any carcinogenic effects.

Reproductive toxicity

- Spinosad: In laboratory animal studies, effects on reproduction have been seen only at doses that produced significant toxicity to the parent animals.

Mutagenicity

- Spinosad: Result in genetic toxicity assays (in vitro and in vivo): Negative.

SECTION 12. ECOLOGICAL INFORMATION

Toxicity to fish

- Spinosad LC50 / 96 h / *Lepomis macrochirus*: 5.94 mg/l
LC50 / 96 h / *Oncorhynchus mykiss*: 30 mg/l

Toxicity to algae

- Spinosad EC50 / *Pseudokirchneriella subcapitata*: >105.5 ppm
EC50 / *Navicula* sp.: 0.107 mg/l

Toxicity to daphnia

- Spinosad EC50 / 48 h / *Daphnia magna* : 92.7 mg/l

SECTION 13. DISPOSAL CONSIDERATIONS

Waste disposal methods : In accordance with local and national regulations.

SECTION 14. TRANSPORT INFORMATION

IMDG	UN Number	: 3077
	Description of the goods	: Environmentally hazardous substance, solid, n.o.s.
	Class	: 9
	Packaging group	: III
	Labels	: 9
	Marine pollutant	: yes

Trifexis

Version 2.4

Revision Date 04/29/2010

Print Date 01/12/2011

Other information : Not dangerous goods in the meaning of DOT.

SECTION 15. REGULATORY INFORMATION**TSCA Status:** Not On TSCA Inventory

131929-60-7	Spinosyn A
131929-63-0	Spinosyn D
93074-04-5	Milbemycin A4 5-oxime
114177-14-9	Milbemycin A3 5-oxime

DSL Status: This product contains the following components that are not on the Canadian DSL nor NDSL lists.

131929-60-7	Spinosyn A
131929-63-0	Spinosyn D
93074-04-5	Milbemycin A4 5-oxime
114177-14-9	Milbemycin A3 5-oxime

California Prop. 65

This product does not contain any chemicals known to the State of California to cause cancer, birth, or any other reproductive defects.

US. EPA Emergency Planning and Community Right-To-Know Act (EPCRA) SARA Title III Section 313 Toxic Chemicals (40 CFR 372.65) - Supplier Notification Required

SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US. EPA Emergency Planning and Community Right-To-Know Act (EPCRA) SARA Title III Section 302 Extremely Hazardous Substance (40 CFR 355, Appendix A)

SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SECTION 16. OTHER INFORMATION**Further information**

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS MATERIAL SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

For additional information contact:
Elanco Companion Animal Health
1-888-545-5973



Trifexis

Version 2.4

Revision Date 04/29/2010

Print Date 01/12/2011